Рain syndrome in the shoulder joint. Clinical significance of bioactive concentrate of small seafish in real clinical practice

Abstract

The limitation of the range of motion of the upper limb in combination with chronic pain syndrome and a decrease in the muscle strength of the arms leads to a significant deterioration in the quality of life of patients, often negatively affects their psychoemotional status, and reduces the ability to work. Arthrosis of the shoulder joint and pathology of the periarticular tissues of the shoulder affect up to 21% of the adult population and up to 33% of people over 60 years of age. Disagreements in the etiology, pathogenesis, terminology, approaches to the diagnosis and treatment of pain syndromes in the shoulder joint area do not contribute to the development of a unified concept of therapy for this pathology. The article provides a review of the literature on the epidemiology and pharmacotherapy of osteoarthritis and soft tissue pathology of the shoulder joint with an analysis of two clinical cases. The peculiarity of the first clinical case is the rapid achievement of therapeutic goals for third grade shoulder osteoarthrosis in an elderly patient with high comorbidity. This allows us to draw conclusions about the predominant role of periarticular tissues inflammation in the generation of severe pain syndrome. The second clinical case presents the dynamics of the development of calcifying tendinitis of the right, later of the left shoulder joint in a woman of working age. The use of a bioactive concentrate of small sea fish (BCSSF) (Alflutop®, Biotechnos) made it possible to quickly reduce the severity of the pain syndrome and return to the usual way of life in the first patient, which made it possible to shorten the use of non-steroidal anti-inflammatory drugs. In the second clinical example, BCSSF promoted the stimulation of regenerative processes in the periarticular tissues of the shoulder joint, the restoration of the function of the dominant limb and the ability to work. Thus, BCSSF may be the drug of choice for patients with osteoarthritis of the shoulder joints with a high risk of cardiovascular and gastrointestinal complications, as well as the drug of choice for a faster recovery of function in case of damage to the periarticular apparatus.